ITPRIPL1 and neoplasm: The extracellular domain of ITPRIPL1 directly binds to the CD3ε extracellular domain, inhibiting TCR‐CD3 signaling and hindering the initial activation of T cells, thus promoting tumor immune escape and progression [31, 32].